Valenta Pharm JSC: Virus Diseases trials

The registry lists 14 Virus Diseases studies with Valenta Pharm JSC as lead sponsor. 3 are open to participants now and 0 have results posted.

Phase 2 1Phase 3 8Phase 4 2No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Efficacy and Safety of XC8, Film-coated Tablets, in Children With Acute Respiratory Viral InfectionsRecruitingNCT06379542Phase 3
• Efficacy and Safety of Ingavirin®, Capsules, 60 mg, in Children With Influenza and Other Acute Respiratory Viral InfectionsRecruitingNCT06315400Phase 4
• Pharmacokinetics and Bioequivalence of Aterixen 100 mg Tablets and Aterixen 100 mg Film-coated Tablets in Healthy VolunteersNot yet recruitingNCT06096571Not applicable
• Pharmacokinetics and Bioequivalence of XC8 10 mg and 40 mg Tablets in Fasted VolunteersCompletedNCT05558462Not applicable
• A Study to Evaluate the Safety and Efficacy of XC221 in Patients With Uncomplicated Influenza or Other Acute Viral Upper Respiratory InfectionsCompletedNCT05544916Phase 3
• Pharmacokinetics and Bioequivalence of Molnupiravir, 200 mg Capsules and Lagevrio, 200 mg Capsules in Healthy VolunteersCompletedNCT05412173Not applicable
• Efficacy and Safety of XC8, Film-coated Tablets, 40 mg in Patients With Dry Non-productive Cough Against Acute Respiratory Viral InfectionCompletedNCT05273619Phase 3
• Efficacy and Safety of XC8, Film-coated Tablets, 10 mg in Patients With Dry Non-productive Cough Against Acute Respiratory Viral InfectionCompletedNCT05269329Phase 2
• Efficacy and Safety of Ingavirin®, Syrup, 30 mg/5 ml, in Children With Influenza and Other Acute Respiratory Viral InfectionsCompletedNCT05269290Phase 3
• Efficacy and Safety Study of Ingavirin® to Treat Influenza and Acute Respiratory Viral Infections in Patients 13-17 y.o.CompletedNCT03206346Phase 3
• Efficacy and Safety Study of Ingavirin® to Treat Influenza and Acute Respiratory Viral Infections in Children 7-12 y.o.CompletedNCT03191097Phase 3
• Study of Post-Exposure Ingavirin® Prophylaxis of Influenza and Acute Respiratory Viral InfectionsCompletedNCT03189537Phase 3
• Efficacy and Safety Study of Ingavirin® 90 mg Once Daily to Treat Influenza and Other Acute Viral Infections in AdultsCompletedNCT03154515Phase 4
• Efficacy and Safety Study of Ingavirin® to Treat Influenza and Other Acute Respiratory Viral Infections in Patients 3-6 y.o.CompletedNCT02644018Phase 3